Review



α orc2  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Santa Cruz Biotechnology α orc2
    (A) Subcellular fractionation and western blotting of WT, ORC2Δ , and <t>ORC2</t> rescue cells. S2, cytoplasmic fraction; S3, nuclear soluble fraction; P3, nuclear insoluble fraction. Asterisk indicates non-specific signal. (B) HP1 foci are unchanged in ORC2Δ cells. Scale bar: 10 μm. (C) H3K9me3 ChIP-seq peaks altered in KO cells and rescued by re-introduction of ORC2. (D) Example H3K9me3 peaks that are dependent on ORC2 and down in the KO (blue) or up in the KO (purple) ( n = 2). (E) ChIP qPCR shows that ORC2 KO does not change H3K9me3 signal on telomeres or centromeres ( n = 3 technical replicates). Data are represented as mean ± SD. (F) Number of bases covered by ORC2-dependent H3K9me3 and K27me3. Red, upregulated in KO and rescued; blue, downregulated in KO and rescued. See also .
    α Orc2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 87 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/α orc2/product/Santa Cruz Biotechnology
    Average 93 stars, based on 87 article reviews
    α orc2 - by Bioz Stars, 2026-05
    93/100 stars

    Images

    1) Product Images from "Regulation of epigenetics and chromosome structure by human ORC2"

    Article Title: Regulation of epigenetics and chromosome structure by human ORC2

    Journal: Cell reports

    doi: 10.1016/j.celrep.2025.115816

    (A) Subcellular fractionation and western blotting of WT, ORC2Δ , and ORC2 rescue cells. S2, cytoplasmic fraction; S3, nuclear soluble fraction; P3, nuclear insoluble fraction. Asterisk indicates non-specific signal. (B) HP1 foci are unchanged in ORC2Δ cells. Scale bar: 10 μm. (C) H3K9me3 ChIP-seq peaks altered in KO cells and rescued by re-introduction of ORC2. (D) Example H3K9me3 peaks that are dependent on ORC2 and down in the KO (blue) or up in the KO (purple) ( n = 2). (E) ChIP qPCR shows that ORC2 KO does not change H3K9me3 signal on telomeres or centromeres ( n = 3 technical replicates). Data are represented as mean ± SD. (F) Number of bases covered by ORC2-dependent H3K9me3 and K27me3. Red, upregulated in KO and rescued; blue, downregulated in KO and rescued. See also .
    Figure Legend Snippet: (A) Subcellular fractionation and western blotting of WT, ORC2Δ , and ORC2 rescue cells. S2, cytoplasmic fraction; S3, nuclear soluble fraction; P3, nuclear insoluble fraction. Asterisk indicates non-specific signal. (B) HP1 foci are unchanged in ORC2Δ cells. Scale bar: 10 μm. (C) H3K9me3 ChIP-seq peaks altered in KO cells and rescued by re-introduction of ORC2. (D) Example H3K9me3 peaks that are dependent on ORC2 and down in the KO (blue) or up in the KO (purple) ( n = 2). (E) ChIP qPCR shows that ORC2 KO does not change H3K9me3 signal on telomeres or centromeres ( n = 3 technical replicates). Data are represented as mean ± SD. (F) Number of bases covered by ORC2-dependent H3K9me3 and K27me3. Red, upregulated in KO and rescued; blue, downregulated in KO and rescued. See also .

    Techniques Used: Fractionation, Western Blot, ChIP-sequencing, ChIP-qPCR

    (A) ATAC-seq peak signals compared in WT and ORC2Δ cells. The significantly up (red) and down (blue) peaks in ORC2Δ are indicated (adjusted p < 0.05, fold change more than 2-fold). (B and C) Heatmap of ATAC signal in the three matched cell lines centered on peaks (B) upregulated or (C) downregulated in the KO cells ( n = 2). (D) Number of ATAC peaks altered in the ORC2Δ . Red indicates the sites where the changes were reversed with re-introduction of ORC2. (E) Enrichment of ORC regulated ATAC peaks in enhancers. (F and G) (F) H3K9me3 and (G) H3K27me3 signal distribution on ATAC-up or ATAC-down peaks in three cell lines. *** p < 0.001 by Student’s t test compared to ORC2Δ . (H and I) Heatmap of ATAC signal centered on (H) centromeres and (I) telomeres in three cell lines. (J) qPCR of ATAC-positive DNA at centromeres of three chromosomes ( n = 3 technical replicates). Data are represented as mean ± SD. See also .
    Figure Legend Snippet: (A) ATAC-seq peak signals compared in WT and ORC2Δ cells. The significantly up (red) and down (blue) peaks in ORC2Δ are indicated (adjusted p < 0.05, fold change more than 2-fold). (B and C) Heatmap of ATAC signal in the three matched cell lines centered on peaks (B) upregulated or (C) downregulated in the KO cells ( n = 2). (D) Number of ATAC peaks altered in the ORC2Δ . Red indicates the sites where the changes were reversed with re-introduction of ORC2. (E) Enrichment of ORC regulated ATAC peaks in enhancers. (F and G) (F) H3K9me3 and (G) H3K27me3 signal distribution on ATAC-up or ATAC-down peaks in three cell lines. *** p < 0.001 by Student’s t test compared to ORC2Δ . (H and I) Heatmap of ATAC signal centered on (H) centromeres and (I) telomeres in three cell lines. (J) qPCR of ATAC-positive DNA at centromeres of three chromosomes ( n = 3 technical replicates). Data are represented as mean ± SD. See also .

    Techniques Used:

    (A) RNA-seq signal of different genes plotted to show mean expression and fold change in ORC2Δ relative to WT ( n = 3). Genes significantly upregulated (red) and downregulated (blue) in the ORC2Δ . (B) Number of genes whose expression is altered in the ORC2Δ . Red indicates genes whose expression change is reversed upon re-introduction of ORC2. (C and D) Heatmap of expression levels of genes that are (C) upregulated or (D) downregulated in the ORC2Δ and rescued ( n = 3). (E) Expression changes of genes in ORC2Δ cells correlated with change of ATAC accessibility in the TSS region. (F and G) (F) CHD7 and (G) NFIA RNA downregulated in an ORC2-dependent manner ( n = 3). Global comparison was by one-way ANOVA test across three cell lines, and pairwise comparison with ORC2Δ was done with Student’s t test (*** p < 0.001, * p < 0.05). (H) Western blot shows CHD7 and NFIA protein decrease on chromatin-bound frac in ORC2Δ and rescue by ORC2. (I and J) H3K27me3 ChIP-seq signal over the (I) CHD7 and (J) NFIA gene in the three cell lines ( n = 2). See also .
    Figure Legend Snippet: (A) RNA-seq signal of different genes plotted to show mean expression and fold change in ORC2Δ relative to WT ( n = 3). Genes significantly upregulated (red) and downregulated (blue) in the ORC2Δ . (B) Number of genes whose expression is altered in the ORC2Δ . Red indicates genes whose expression change is reversed upon re-introduction of ORC2. (C and D) Heatmap of expression levels of genes that are (C) upregulated or (D) downregulated in the ORC2Δ and rescued ( n = 3). (E) Expression changes of genes in ORC2Δ cells correlated with change of ATAC accessibility in the TSS region. (F and G) (F) CHD7 and (G) NFIA RNA downregulated in an ORC2-dependent manner ( n = 3). Global comparison was by one-way ANOVA test across three cell lines, and pairwise comparison with ORC2Δ was done with Student’s t test (*** p < 0.001, * p < 0.05). (H) Western blot shows CHD7 and NFIA protein decrease on chromatin-bound frac in ORC2Δ and rescue by ORC2. (I and J) H3K27me3 ChIP-seq signal over the (I) CHD7 and (J) NFIA gene in the three cell lines ( n = 2). See also .

    Techniques Used: RNA Sequencing, Expressing, Comparison, Western Blot, ChIP-sequencing

    (A) Schematic of experiment. (B and C) Chromatin-accessibility (ATAC-seq) and gene-expression (RNA-seq) changes in ORC1Δ . Signals significantly upregulated (red) or downregulated (blue) in the ORC1Δ cells. (D and E) Same as (B) and (C) except for ORC5Δ cells relative to WT. (F and G) Venn diagrams showing overlap of ATAC changes in the three KO cells. (H) Example ORC2-dependent ATAC changes (chr19: 608305–614483; chr2: 28407886–2841 1076; chr13: 21031256–21037283; chr17: 72,698,613–72,700,987). (I and J) Venn diagram showing overlap of gene-expression changes in the three KO cells. See also .
    Figure Legend Snippet: (A) Schematic of experiment. (B and C) Chromatin-accessibility (ATAC-seq) and gene-expression (RNA-seq) changes in ORC1Δ . Signals significantly upregulated (red) or downregulated (blue) in the ORC1Δ cells. (D and E) Same as (B) and (C) except for ORC5Δ cells relative to WT. (F and G) Venn diagrams showing overlap of ATAC changes in the three KO cells. (H) Example ORC2-dependent ATAC changes (chr19: 608305–614483; chr2: 28407886–2841 1076; chr13: 21031256–21037283; chr17: 72,698,613–72,700,987). (I and J) Venn diagram showing overlap of gene-expression changes in the three KO cells. See also .

    Techniques Used: Gene Expression, RNA Sequencing

    (A) Schematic of ChEC-seq experiments to identify binding sites of ORC subunits. (B) Number of peaks bound by each of the three ORC subunits and their overlap. (C and D) Heatmap of binding of the three subunits centered on sites bound by (C) ORC2 or (D) TSSs ( n = 2). (E) Enrichment of binding sites of ORC subunits on enhancers and promoters. (F) ORC2-binding sites are enriched at sites that become more accessible (ATAC-up) when ORC2 is lost. A lesser enrichment is seen at ATAC-down sites. Z and p value are derived from permutation test ( n = 1,000), *** p < 0.001. (G) BART analysis of transcription factors whose known-binding sites are enriched near ORC2-binding sites. See also .
    Figure Legend Snippet: (A) Schematic of ChEC-seq experiments to identify binding sites of ORC subunits. (B) Number of peaks bound by each of the three ORC subunits and their overlap. (C and D) Heatmap of binding of the three subunits centered on sites bound by (C) ORC2 or (D) TSSs ( n = 2). (E) Enrichment of binding sites of ORC subunits on enhancers and promoters. (F) ORC2-binding sites are enriched at sites that become more accessible (ATAC-up) when ORC2 is lost. A lesser enrichment is seen at ATAC-down sites. Z and p value are derived from permutation test ( n = 1,000), *** p < 0.001. (G) BART analysis of transcription factors whose known-binding sites are enriched near ORC2-binding sites. See also .

    Techniques Used: Binding Assay, Derivative Assay

    (A) Example compartment changes on Chr 16 from A (red) to B in the ORC2Δ cells and is rescued by ORC2 restoration. The H3K9me3 and H3K27me3 tracks ( n = 2) are shown. (B) Changes in PC1 when the KO is compared to the WT ( x axis) or the rescue ( y axis) are correlated with each other at many more sites than show sign (compartment) changes. Colors of the dots represent compartment status in the ORC2Δ (red, A compar; cyan, B). (C) Number of loops that increase or decrease in the KO relative to WT, and the portion that is rescued by ORC2 restoration. (D) Heatmap of loop strength of the loops (up or down) that are rescued in (C). (E) Loops that become stronger in the KO are longer than the loops that become weaker. (F) Enrichment of ORC2-binding sites across the region centered on loop-up or loop-down sites. (G) Enrichment of loop-up anchors across the region centered on loop-down anchors. See also .
    Figure Legend Snippet: (A) Example compartment changes on Chr 16 from A (red) to B in the ORC2Δ cells and is rescued by ORC2 restoration. The H3K9me3 and H3K27me3 tracks ( n = 2) are shown. (B) Changes in PC1 when the KO is compared to the WT ( x axis) or the rescue ( y axis) are correlated with each other at many more sites than show sign (compartment) changes. Colors of the dots represent compartment status in the ORC2Δ (red, A compar; cyan, B). (C) Number of loops that increase or decrease in the KO relative to WT, and the portion that is rescued by ORC2 restoration. (D) Heatmap of loop strength of the loops (up or down) that are rescued in (C). (E) Loops that become stronger in the KO are longer than the loops that become weaker. (F) Enrichment of ORC2-binding sites across the region centered on loop-up or loop-down sites. (G) Enrichment of loop-up anchors across the region centered on loop-down anchors. See also .

    Techniques Used: Binding Assay

    (A) Venn diagram of CTCF-binding sites in the three cell lines. Red, CTCF-binding sites that are increased in the KO and decreased in the rescue; blue, CTCF-binding sites present in the WT that disappeared in the KO and re-appeared when ORC2 is restored. (B) CTCF motif enrichment ratio in indicated classes of CTCF-binding sites. (C) Enrichment of ORC2-binding sites across the region centered on CTCF-binding sites of the three classes by permutation test ( n = 1,000). (D) Enrichment of ATAC-up or -down sites at CTCF-binding sites of the three classes by permutation test ( n = 1,000). (E) Top three tracks: Loops in the NFIA locus in the three cell lines. The loop anchor sites a–f are indicated at the top and marked by the colored bars running through all tracks. ORC2- and CTCF-binding sites are shown in the middle tracks. Bottom three tracks: ORC2-dependent prevention of H3K27me3 mark at the locus. See also .
    Figure Legend Snippet: (A) Venn diagram of CTCF-binding sites in the three cell lines. Red, CTCF-binding sites that are increased in the KO and decreased in the rescue; blue, CTCF-binding sites present in the WT that disappeared in the KO and re-appeared when ORC2 is restored. (B) CTCF motif enrichment ratio in indicated classes of CTCF-binding sites. (C) Enrichment of ORC2-binding sites across the region centered on CTCF-binding sites of the three classes by permutation test ( n = 1,000). (D) Enrichment of ATAC-up or -down sites at CTCF-binding sites of the three classes by permutation test ( n = 1,000). (E) Top three tracks: Loops in the NFIA locus in the three cell lines. The loop anchor sites a–f are indicated at the top and marked by the colored bars running through all tracks. ORC2- and CTCF-binding sites are shown in the middle tracks. Bottom three tracks: ORC2-dependent prevention of H3K27me3 mark at the locus. See also .

    Techniques Used: Binding Assay



    Similar Products

    93
    Santa Cruz Biotechnology α orc2
    (A) Subcellular fractionation and western blotting of WT, ORC2Δ , and <t>ORC2</t> rescue cells. S2, cytoplasmic fraction; S3, nuclear soluble fraction; P3, nuclear insoluble fraction. Asterisk indicates non-specific signal. (B) HP1 foci are unchanged in ORC2Δ cells. Scale bar: 10 μm. (C) H3K9me3 ChIP-seq peaks altered in KO cells and rescued by re-introduction of ORC2. (D) Example H3K9me3 peaks that are dependent on ORC2 and down in the KO (blue) or up in the KO (purple) ( n = 2). (E) ChIP qPCR shows that ORC2 KO does not change H3K9me3 signal on telomeres or centromeres ( n = 3 technical replicates). Data are represented as mean ± SD. (F) Number of bases covered by ORC2-dependent H3K9me3 and K27me3. Red, upregulated in KO and rescued; blue, downregulated in KO and rescued. See also .
    α Orc2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/α orc2/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    α orc2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology goat polyclonal α orc2
    (A) Subcellular fractionation and western blotting of WT, ORC2Δ , and <t>ORC2</t> rescue cells. S2, cytoplasmic fraction; S3, nuclear soluble fraction; P3, nuclear insoluble fraction. Asterisk indicates non-specific signal. (B) HP1 foci are unchanged in ORC2Δ cells. Scale bar: 10 μm. (C) H3K9me3 ChIP-seq peaks altered in KO cells and rescued by re-introduction of ORC2. (D) Example H3K9me3 peaks that are dependent on ORC2 and down in the KO (blue) or up in the KO (purple) ( n = 2). (E) ChIP qPCR shows that ORC2 KO does not change H3K9me3 signal on telomeres or centromeres ( n = 3 technical replicates). Data are represented as mean ± SD. (F) Number of bases covered by ORC2-dependent H3K9me3 and K27me3. Red, upregulated in KO and rescued; blue, downregulated in KO and rescued. See also .
    Goat Polyclonal α Orc2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat polyclonal α orc2/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    goat polyclonal α orc2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology monoclonal anti orc2 α orc2 antibody
    (A) Subcellular fractionation and western blotting of WT, ORC2Δ , and <t>ORC2</t> rescue cells. S2, cytoplasmic fraction; S3, nuclear soluble fraction; P3, nuclear insoluble fraction. Asterisk indicates non-specific signal. (B) HP1 foci are unchanged in ORC2Δ cells. Scale bar: 10 μm. (C) H3K9me3 ChIP-seq peaks altered in KO cells and rescued by re-introduction of ORC2. (D) Example H3K9me3 peaks that are dependent on ORC2 and down in the KO (blue) or up in the KO (purple) ( n = 2). (E) ChIP qPCR shows that ORC2 KO does not change H3K9me3 signal on telomeres or centromeres ( n = 3 technical replicates). Data are represented as mean ± SD. (F) Number of bases covered by ORC2-dependent H3K9me3 and K27me3. Red, upregulated in KO and rescued; blue, downregulated in KO and rescued. See also .
    Monoclonal Anti Orc2 α Orc2 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal anti orc2 α orc2 antibody/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    monoclonal anti orc2 α orc2 antibody - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    (A) Subcellular fractionation and western blotting of WT, ORC2Δ , and ORC2 rescue cells. S2, cytoplasmic fraction; S3, nuclear soluble fraction; P3, nuclear insoluble fraction. Asterisk indicates non-specific signal. (B) HP1 foci are unchanged in ORC2Δ cells. Scale bar: 10 μm. (C) H3K9me3 ChIP-seq peaks altered in KO cells and rescued by re-introduction of ORC2. (D) Example H3K9me3 peaks that are dependent on ORC2 and down in the KO (blue) or up in the KO (purple) ( n = 2). (E) ChIP qPCR shows that ORC2 KO does not change H3K9me3 signal on telomeres or centromeres ( n = 3 technical replicates). Data are represented as mean ± SD. (F) Number of bases covered by ORC2-dependent H3K9me3 and K27me3. Red, upregulated in KO and rescued; blue, downregulated in KO and rescued. See also .

    Journal: Cell reports

    Article Title: Regulation of epigenetics and chromosome structure by human ORC2

    doi: 10.1016/j.celrep.2025.115816

    Figure Lengend Snippet: (A) Subcellular fractionation and western blotting of WT, ORC2Δ , and ORC2 rescue cells. S2, cytoplasmic fraction; S3, nuclear soluble fraction; P3, nuclear insoluble fraction. Asterisk indicates non-specific signal. (B) HP1 foci are unchanged in ORC2Δ cells. Scale bar: 10 μm. (C) H3K9me3 ChIP-seq peaks altered in KO cells and rescued by re-introduction of ORC2. (D) Example H3K9me3 peaks that are dependent on ORC2 and down in the KO (blue) or up in the KO (purple) ( n = 2). (E) ChIP qPCR shows that ORC2 KO does not change H3K9me3 signal on telomeres or centromeres ( n = 3 technical replicates). Data are represented as mean ± SD. (F) Number of bases covered by ORC2-dependent H3K9me3 and K27me3. Red, upregulated in KO and rescued; blue, downregulated in KO and rescued. See also .

    Article Snippet: Antibodies used include α-ORC1 (cell signaling technology, no. 4731), α-ORC2 (Santa Cruz Biotechnology, no. sc-32734), α-ORC3 (Santa Cruz Biotechnology, no. sc-23888), α-ORC4, α-ORC5, α-ORC6 (home-made ), α-HSP90 (Santa Cruz Biotechnology, no. sc-13119), α-MCM7 (Santa Cruz Biotechnology, no. sc-9966), α-ORCA (a generous gift from Supriya G. Prasanth, University of Illinois ), α-HP1α (cell signaling technology, no. 2616), α-H3K9ME1 (cell signaling technology, no. 14186), α-H3K9ME2 (cell signaling technology, no. 4658), α-H3K9ME3 (cell signaling technology, no. 13969), α-HBO1 (cell signaling technology, no. 58418), α-H3K27ME3 (cell signaling technology, no. 9733), α-Histone H3 (cell signaling technology, no. 4499), α-NFIA (Abcepta, no. AP20998c), α-CHD7 (cell signaling technology, no. 6505).

    Techniques: Fractionation, Western Blot, ChIP-sequencing, ChIP-qPCR

    (A) ATAC-seq peak signals compared in WT and ORC2Δ cells. The significantly up (red) and down (blue) peaks in ORC2Δ are indicated (adjusted p < 0.05, fold change more than 2-fold). (B and C) Heatmap of ATAC signal in the three matched cell lines centered on peaks (B) upregulated or (C) downregulated in the KO cells ( n = 2). (D) Number of ATAC peaks altered in the ORC2Δ . Red indicates the sites where the changes were reversed with re-introduction of ORC2. (E) Enrichment of ORC regulated ATAC peaks in enhancers. (F and G) (F) H3K9me3 and (G) H3K27me3 signal distribution on ATAC-up or ATAC-down peaks in three cell lines. *** p < 0.001 by Student’s t test compared to ORC2Δ . (H and I) Heatmap of ATAC signal centered on (H) centromeres and (I) telomeres in three cell lines. (J) qPCR of ATAC-positive DNA at centromeres of three chromosomes ( n = 3 technical replicates). Data are represented as mean ± SD. See also .

    Journal: Cell reports

    Article Title: Regulation of epigenetics and chromosome structure by human ORC2

    doi: 10.1016/j.celrep.2025.115816

    Figure Lengend Snippet: (A) ATAC-seq peak signals compared in WT and ORC2Δ cells. The significantly up (red) and down (blue) peaks in ORC2Δ are indicated (adjusted p < 0.05, fold change more than 2-fold). (B and C) Heatmap of ATAC signal in the three matched cell lines centered on peaks (B) upregulated or (C) downregulated in the KO cells ( n = 2). (D) Number of ATAC peaks altered in the ORC2Δ . Red indicates the sites where the changes were reversed with re-introduction of ORC2. (E) Enrichment of ORC regulated ATAC peaks in enhancers. (F and G) (F) H3K9me3 and (G) H3K27me3 signal distribution on ATAC-up or ATAC-down peaks in three cell lines. *** p < 0.001 by Student’s t test compared to ORC2Δ . (H and I) Heatmap of ATAC signal centered on (H) centromeres and (I) telomeres in three cell lines. (J) qPCR of ATAC-positive DNA at centromeres of three chromosomes ( n = 3 technical replicates). Data are represented as mean ± SD. See also .

    Article Snippet: Antibodies used include α-ORC1 (cell signaling technology, no. 4731), α-ORC2 (Santa Cruz Biotechnology, no. sc-32734), α-ORC3 (Santa Cruz Biotechnology, no. sc-23888), α-ORC4, α-ORC5, α-ORC6 (home-made ), α-HSP90 (Santa Cruz Biotechnology, no. sc-13119), α-MCM7 (Santa Cruz Biotechnology, no. sc-9966), α-ORCA (a generous gift from Supriya G. Prasanth, University of Illinois ), α-HP1α (cell signaling technology, no. 2616), α-H3K9ME1 (cell signaling technology, no. 14186), α-H3K9ME2 (cell signaling technology, no. 4658), α-H3K9ME3 (cell signaling technology, no. 13969), α-HBO1 (cell signaling technology, no. 58418), α-H3K27ME3 (cell signaling technology, no. 9733), α-Histone H3 (cell signaling technology, no. 4499), α-NFIA (Abcepta, no. AP20998c), α-CHD7 (cell signaling technology, no. 6505).

    Techniques:

    (A) RNA-seq signal of different genes plotted to show mean expression and fold change in ORC2Δ relative to WT ( n = 3). Genes significantly upregulated (red) and downregulated (blue) in the ORC2Δ . (B) Number of genes whose expression is altered in the ORC2Δ . Red indicates genes whose expression change is reversed upon re-introduction of ORC2. (C and D) Heatmap of expression levels of genes that are (C) upregulated or (D) downregulated in the ORC2Δ and rescued ( n = 3). (E) Expression changes of genes in ORC2Δ cells correlated with change of ATAC accessibility in the TSS region. (F and G) (F) CHD7 and (G) NFIA RNA downregulated in an ORC2-dependent manner ( n = 3). Global comparison was by one-way ANOVA test across three cell lines, and pairwise comparison with ORC2Δ was done with Student’s t test (*** p < 0.001, * p < 0.05). (H) Western blot shows CHD7 and NFIA protein decrease on chromatin-bound frac in ORC2Δ and rescue by ORC2. (I and J) H3K27me3 ChIP-seq signal over the (I) CHD7 and (J) NFIA gene in the three cell lines ( n = 2). See also .

    Journal: Cell reports

    Article Title: Regulation of epigenetics and chromosome structure by human ORC2

    doi: 10.1016/j.celrep.2025.115816

    Figure Lengend Snippet: (A) RNA-seq signal of different genes plotted to show mean expression and fold change in ORC2Δ relative to WT ( n = 3). Genes significantly upregulated (red) and downregulated (blue) in the ORC2Δ . (B) Number of genes whose expression is altered in the ORC2Δ . Red indicates genes whose expression change is reversed upon re-introduction of ORC2. (C and D) Heatmap of expression levels of genes that are (C) upregulated or (D) downregulated in the ORC2Δ and rescued ( n = 3). (E) Expression changes of genes in ORC2Δ cells correlated with change of ATAC accessibility in the TSS region. (F and G) (F) CHD7 and (G) NFIA RNA downregulated in an ORC2-dependent manner ( n = 3). Global comparison was by one-way ANOVA test across three cell lines, and pairwise comparison with ORC2Δ was done with Student’s t test (*** p < 0.001, * p < 0.05). (H) Western blot shows CHD7 and NFIA protein decrease on chromatin-bound frac in ORC2Δ and rescue by ORC2. (I and J) H3K27me3 ChIP-seq signal over the (I) CHD7 and (J) NFIA gene in the three cell lines ( n = 2). See also .

    Article Snippet: Antibodies used include α-ORC1 (cell signaling technology, no. 4731), α-ORC2 (Santa Cruz Biotechnology, no. sc-32734), α-ORC3 (Santa Cruz Biotechnology, no. sc-23888), α-ORC4, α-ORC5, α-ORC6 (home-made ), α-HSP90 (Santa Cruz Biotechnology, no. sc-13119), α-MCM7 (Santa Cruz Biotechnology, no. sc-9966), α-ORCA (a generous gift from Supriya G. Prasanth, University of Illinois ), α-HP1α (cell signaling technology, no. 2616), α-H3K9ME1 (cell signaling technology, no. 14186), α-H3K9ME2 (cell signaling technology, no. 4658), α-H3K9ME3 (cell signaling technology, no. 13969), α-HBO1 (cell signaling technology, no. 58418), α-H3K27ME3 (cell signaling technology, no. 9733), α-Histone H3 (cell signaling technology, no. 4499), α-NFIA (Abcepta, no. AP20998c), α-CHD7 (cell signaling technology, no. 6505).

    Techniques: RNA Sequencing, Expressing, Comparison, Western Blot, ChIP-sequencing

    (A) Schematic of experiment. (B and C) Chromatin-accessibility (ATAC-seq) and gene-expression (RNA-seq) changes in ORC1Δ . Signals significantly upregulated (red) or downregulated (blue) in the ORC1Δ cells. (D and E) Same as (B) and (C) except for ORC5Δ cells relative to WT. (F and G) Venn diagrams showing overlap of ATAC changes in the three KO cells. (H) Example ORC2-dependent ATAC changes (chr19: 608305–614483; chr2: 28407886–2841 1076; chr13: 21031256–21037283; chr17: 72,698,613–72,700,987). (I and J) Venn diagram showing overlap of gene-expression changes in the three KO cells. See also .

    Journal: Cell reports

    Article Title: Regulation of epigenetics and chromosome structure by human ORC2

    doi: 10.1016/j.celrep.2025.115816

    Figure Lengend Snippet: (A) Schematic of experiment. (B and C) Chromatin-accessibility (ATAC-seq) and gene-expression (RNA-seq) changes in ORC1Δ . Signals significantly upregulated (red) or downregulated (blue) in the ORC1Δ cells. (D and E) Same as (B) and (C) except for ORC5Δ cells relative to WT. (F and G) Venn diagrams showing overlap of ATAC changes in the three KO cells. (H) Example ORC2-dependent ATAC changes (chr19: 608305–614483; chr2: 28407886–2841 1076; chr13: 21031256–21037283; chr17: 72,698,613–72,700,987). (I and J) Venn diagram showing overlap of gene-expression changes in the three KO cells. See also .

    Article Snippet: Antibodies used include α-ORC1 (cell signaling technology, no. 4731), α-ORC2 (Santa Cruz Biotechnology, no. sc-32734), α-ORC3 (Santa Cruz Biotechnology, no. sc-23888), α-ORC4, α-ORC5, α-ORC6 (home-made ), α-HSP90 (Santa Cruz Biotechnology, no. sc-13119), α-MCM7 (Santa Cruz Biotechnology, no. sc-9966), α-ORCA (a generous gift from Supriya G. Prasanth, University of Illinois ), α-HP1α (cell signaling technology, no. 2616), α-H3K9ME1 (cell signaling technology, no. 14186), α-H3K9ME2 (cell signaling technology, no. 4658), α-H3K9ME3 (cell signaling technology, no. 13969), α-HBO1 (cell signaling technology, no. 58418), α-H3K27ME3 (cell signaling technology, no. 9733), α-Histone H3 (cell signaling technology, no. 4499), α-NFIA (Abcepta, no. AP20998c), α-CHD7 (cell signaling technology, no. 6505).

    Techniques: Gene Expression, RNA Sequencing

    (A) Schematic of ChEC-seq experiments to identify binding sites of ORC subunits. (B) Number of peaks bound by each of the three ORC subunits and their overlap. (C and D) Heatmap of binding of the three subunits centered on sites bound by (C) ORC2 or (D) TSSs ( n = 2). (E) Enrichment of binding sites of ORC subunits on enhancers and promoters. (F) ORC2-binding sites are enriched at sites that become more accessible (ATAC-up) when ORC2 is lost. A lesser enrichment is seen at ATAC-down sites. Z and p value are derived from permutation test ( n = 1,000), *** p < 0.001. (G) BART analysis of transcription factors whose known-binding sites are enriched near ORC2-binding sites. See also .

    Journal: Cell reports

    Article Title: Regulation of epigenetics and chromosome structure by human ORC2

    doi: 10.1016/j.celrep.2025.115816

    Figure Lengend Snippet: (A) Schematic of ChEC-seq experiments to identify binding sites of ORC subunits. (B) Number of peaks bound by each of the three ORC subunits and their overlap. (C and D) Heatmap of binding of the three subunits centered on sites bound by (C) ORC2 or (D) TSSs ( n = 2). (E) Enrichment of binding sites of ORC subunits on enhancers and promoters. (F) ORC2-binding sites are enriched at sites that become more accessible (ATAC-up) when ORC2 is lost. A lesser enrichment is seen at ATAC-down sites. Z and p value are derived from permutation test ( n = 1,000), *** p < 0.001. (G) BART analysis of transcription factors whose known-binding sites are enriched near ORC2-binding sites. See also .

    Article Snippet: Antibodies used include α-ORC1 (cell signaling technology, no. 4731), α-ORC2 (Santa Cruz Biotechnology, no. sc-32734), α-ORC3 (Santa Cruz Biotechnology, no. sc-23888), α-ORC4, α-ORC5, α-ORC6 (home-made ), α-HSP90 (Santa Cruz Biotechnology, no. sc-13119), α-MCM7 (Santa Cruz Biotechnology, no. sc-9966), α-ORCA (a generous gift from Supriya G. Prasanth, University of Illinois ), α-HP1α (cell signaling technology, no. 2616), α-H3K9ME1 (cell signaling technology, no. 14186), α-H3K9ME2 (cell signaling technology, no. 4658), α-H3K9ME3 (cell signaling technology, no. 13969), α-HBO1 (cell signaling technology, no. 58418), α-H3K27ME3 (cell signaling technology, no. 9733), α-Histone H3 (cell signaling technology, no. 4499), α-NFIA (Abcepta, no. AP20998c), α-CHD7 (cell signaling technology, no. 6505).

    Techniques: Binding Assay, Derivative Assay

    (A) Example compartment changes on Chr 16 from A (red) to B in the ORC2Δ cells and is rescued by ORC2 restoration. The H3K9me3 and H3K27me3 tracks ( n = 2) are shown. (B) Changes in PC1 when the KO is compared to the WT ( x axis) or the rescue ( y axis) are correlated with each other at many more sites than show sign (compartment) changes. Colors of the dots represent compartment status in the ORC2Δ (red, A compar; cyan, B). (C) Number of loops that increase or decrease in the KO relative to WT, and the portion that is rescued by ORC2 restoration. (D) Heatmap of loop strength of the loops (up or down) that are rescued in (C). (E) Loops that become stronger in the KO are longer than the loops that become weaker. (F) Enrichment of ORC2-binding sites across the region centered on loop-up or loop-down sites. (G) Enrichment of loop-up anchors across the region centered on loop-down anchors. See also .

    Journal: Cell reports

    Article Title: Regulation of epigenetics and chromosome structure by human ORC2

    doi: 10.1016/j.celrep.2025.115816

    Figure Lengend Snippet: (A) Example compartment changes on Chr 16 from A (red) to B in the ORC2Δ cells and is rescued by ORC2 restoration. The H3K9me3 and H3K27me3 tracks ( n = 2) are shown. (B) Changes in PC1 when the KO is compared to the WT ( x axis) or the rescue ( y axis) are correlated with each other at many more sites than show sign (compartment) changes. Colors of the dots represent compartment status in the ORC2Δ (red, A compar; cyan, B). (C) Number of loops that increase or decrease in the KO relative to WT, and the portion that is rescued by ORC2 restoration. (D) Heatmap of loop strength of the loops (up or down) that are rescued in (C). (E) Loops that become stronger in the KO are longer than the loops that become weaker. (F) Enrichment of ORC2-binding sites across the region centered on loop-up or loop-down sites. (G) Enrichment of loop-up anchors across the region centered on loop-down anchors. See also .

    Article Snippet: Antibodies used include α-ORC1 (cell signaling technology, no. 4731), α-ORC2 (Santa Cruz Biotechnology, no. sc-32734), α-ORC3 (Santa Cruz Biotechnology, no. sc-23888), α-ORC4, α-ORC5, α-ORC6 (home-made ), α-HSP90 (Santa Cruz Biotechnology, no. sc-13119), α-MCM7 (Santa Cruz Biotechnology, no. sc-9966), α-ORCA (a generous gift from Supriya G. Prasanth, University of Illinois ), α-HP1α (cell signaling technology, no. 2616), α-H3K9ME1 (cell signaling technology, no. 14186), α-H3K9ME2 (cell signaling technology, no. 4658), α-H3K9ME3 (cell signaling technology, no. 13969), α-HBO1 (cell signaling technology, no. 58418), α-H3K27ME3 (cell signaling technology, no. 9733), α-Histone H3 (cell signaling technology, no. 4499), α-NFIA (Abcepta, no. AP20998c), α-CHD7 (cell signaling technology, no. 6505).

    Techniques: Binding Assay

    (A) Venn diagram of CTCF-binding sites in the three cell lines. Red, CTCF-binding sites that are increased in the KO and decreased in the rescue; blue, CTCF-binding sites present in the WT that disappeared in the KO and re-appeared when ORC2 is restored. (B) CTCF motif enrichment ratio in indicated classes of CTCF-binding sites. (C) Enrichment of ORC2-binding sites across the region centered on CTCF-binding sites of the three classes by permutation test ( n = 1,000). (D) Enrichment of ATAC-up or -down sites at CTCF-binding sites of the three classes by permutation test ( n = 1,000). (E) Top three tracks: Loops in the NFIA locus in the three cell lines. The loop anchor sites a–f are indicated at the top and marked by the colored bars running through all tracks. ORC2- and CTCF-binding sites are shown in the middle tracks. Bottom three tracks: ORC2-dependent prevention of H3K27me3 mark at the locus. See also .

    Journal: Cell reports

    Article Title: Regulation of epigenetics and chromosome structure by human ORC2

    doi: 10.1016/j.celrep.2025.115816

    Figure Lengend Snippet: (A) Venn diagram of CTCF-binding sites in the three cell lines. Red, CTCF-binding sites that are increased in the KO and decreased in the rescue; blue, CTCF-binding sites present in the WT that disappeared in the KO and re-appeared when ORC2 is restored. (B) CTCF motif enrichment ratio in indicated classes of CTCF-binding sites. (C) Enrichment of ORC2-binding sites across the region centered on CTCF-binding sites of the three classes by permutation test ( n = 1,000). (D) Enrichment of ATAC-up or -down sites at CTCF-binding sites of the three classes by permutation test ( n = 1,000). (E) Top three tracks: Loops in the NFIA locus in the three cell lines. The loop anchor sites a–f are indicated at the top and marked by the colored bars running through all tracks. ORC2- and CTCF-binding sites are shown in the middle tracks. Bottom three tracks: ORC2-dependent prevention of H3K27me3 mark at the locus. See also .

    Article Snippet: Antibodies used include α-ORC1 (cell signaling technology, no. 4731), α-ORC2 (Santa Cruz Biotechnology, no. sc-32734), α-ORC3 (Santa Cruz Biotechnology, no. sc-23888), α-ORC4, α-ORC5, α-ORC6 (home-made ), α-HSP90 (Santa Cruz Biotechnology, no. sc-13119), α-MCM7 (Santa Cruz Biotechnology, no. sc-9966), α-ORCA (a generous gift from Supriya G. Prasanth, University of Illinois ), α-HP1α (cell signaling technology, no. 2616), α-H3K9ME1 (cell signaling technology, no. 14186), α-H3K9ME2 (cell signaling technology, no. 4658), α-H3K9ME3 (cell signaling technology, no. 13969), α-HBO1 (cell signaling technology, no. 58418), α-H3K27ME3 (cell signaling technology, no. 9733), α-Histone H3 (cell signaling technology, no. 4499), α-NFIA (Abcepta, no. AP20998c), α-CHD7 (cell signaling technology, no. 6505).

    Techniques: Binding Assay